PERSPECTA

News from every angle

← Back to headlines

Astellas Begins Phase 3 Trial for Gastric Cancer Drug ASP2138

Astellas has dosed its first patient in a Phase 3 study for ASP2138, a drug targeting CLDN18.2-positive and HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. This marks a significant step in the drug's development for gastric cancer treatment.

25 Aug, 00:23 — 25 Aug, 00:23
PostShare

Sources

Showing 1 of 2 sources
morningstar10h ago

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma - Morningstar

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma  Morningstar

Read full article →

Coverage Timeline

First report: morningstar · 25 Aug, 00:23Full coverage: 2 · 7hWindow: 7h
Left-leaningCenterRight-leaning
morningstar25 Aug, 00:23First to report

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma - Morningstar

7h later
investing-com25 Aug, 07:00Latest update

Senhwa completes enrollment in phase 1b cancer drug trial

Related Stories

US and UAE Impose New Sanctions and Trade Embargoes on Iran

6m ago

Serbia's Average Net Salary Reaches 1,026 Euros in June

25m ago

Iran Vows Retaliation After New US Sanctions

36m ago

Giannis Stasinopoulos Acquires Full Ownership of Active Computer Systems

40m ago